Cue Biopharma, Inc. is an innovative biopharmaceutical company that aims to revolutionize the treatment of cancer and autoimmune diseases by developing drugs that modulate the human immune system. Using advanced scientific methods, it has established a robust platform to design and engineer specific therapeutic agents that can directly engage and modulate targeted T cells within the patient's body.
The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. Cue Biopharma shares have been trading on NASDAQ (under the symbol CUE) since December 2017. The company's unique innovation, Immuno-STAT Biologics, stands for Selective Targeting and Alteration of T Cells. This technology is a modular system designed to develop precision therapeutic antibodies that can be tailored to target specific disease-associated T cell populations.
What sets Cue Biopharma apart is that their Immuno-STAT platform doesn't just activate the immune system generically. Instead, it enables the precise targeting of particular disease-associated T cell populations. Also, it modulates T cells in their natural environments in the body, offering the potential for better therapeutic outcomes and fewer side effects. The platform is flexible, so it can be tailored to treat a broad range of serious diseases.
Cue Biopharma has a portfolio of preclinical and clinical programs aimed at treating various cancers and autoimmune diseases. The company's lead program, CUE-101, targets specific types of HPV-associated cancers by engaging and modulating T cells to attack the disease. Further programs are being developed for cancers such as melanoma and autoimmune diseases, including lupus and rheumatoid arthritis amongst others.
At Cue Biopharma, collaboration is critical as it not only works with research and academic institutions but also forms strategic alliances with prominent pharmaceutical companies to further advance its programs. It also dedicates substantial resources to expand its orthogonal portfolio to push beyond cancer into other disease areas such as autoimmunity and chronic infectious disease.
Finally, Cue Biopharma isn’t just interested in delivering drugs, but also in improving the cost and time efficiencies of drug development. The modular nature of its platform is intended to reduce the time and expense of the drug development process. Overall, Cue Biopharma, Inc. is committed to its lofty mission of developing therapies that improve and extend the lives of patients with diverse immune system ailments.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Ray Sumita, Corporate Secretary of Cue Biopharma, Inc., filed a Form 144 notice for the proposed sale of 1844 shares of common stock valued at $51,724.20. These sales are intended to cover tax withholding obligations associated with the vesting of restricted stock units and do not represent discretionary transactions. The notice indicates the shares were acquired on October 9, 2026, through restricted stock units vesting under a registered plan.
Cue Biopharma reported positive Phase 2 results for CUE-221 in treating chronic spontaneous urticaria (hives), showing complete resolution in 54% of patients at the highest dose compared to 11% for placebo. A key differentiator is the observed sustained relief after treatment cessation, with 60% of the highest-dose group maintaining complete resolution 12 weeks post-treatment, suggesting a potential advantage over existing options like omalizumab. The company plans a Phase 2b/3 study, but acknowledges the need to confirm these exploratory findings and durability in larger trials.
Cue Biopharma (CUE) is being initiated with a 'Buy' rating due to positive phase 2 trial results for CUE-221 in chronic spontaneous urticaria (CSU). CUE-221, with its novel dual mechanism of action, showed superior efficacy to XOLAIR, with 54% of patients achieving complete hive resolution. Upcoming catalysts include 36-week PK and IgE data in 2026 and planned global phase 2b/3 studies, though the company faces a limited cash runway despite recent financing.